116057-75-1
116057-75-1
Chemical Structure
Idoxifene
Synonym(s): CB7432
- CAS No.: 116057-75-1
- Formula:C28H30INO
- Molecular Weight:523.45
IUPAC Name: (E)-1-(2-(4-(1-(4-iodophenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)pyrrolidine
InChIKey: JJKOTMDDZAJTGQ-DQSJHHFOSA-N
SMILES: CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN3CCCC3)C=C2)\C4=CC=C(I)C=C4
Biological Activity: Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM).
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Idoxifene | 99.43% | Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Idoxifene (Standard) | ≥98% | Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RID-F | RID-F (Ridaifen-F), a Tamoxifen (HY-13757A) derivative, is a nonpeptidic proteasome inhibitor. RID-F inhibits human 20S proteasome activity, with IC50s of 0.64, 0.34, and 0.43 μM for CT-L, T-L, and PGPH, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
4-Hydroxytamoxifen | 99.86% | 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(E/Z)-4-Hydroxytamoxifen | 99.62% | (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(E)-4-Hydroxytamoxifen | 97.0% | (E)-4-Hydroxytamoxifen ((E)-Afimoxifene), the less active isomer of (Z)-4-hydroxytamoxifen, is an estrogen receptor modulator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Z)-Norendoxifen | (Z)-Norendoxifen is an aromatase inhibitor and estrogen receptor modulator. The IC50 value of (Z)-Norendoxifen against aromatase is 102 nM. The EC50 values of (Z)-Norendoxifen for ER-α and ER-β are 27.0 nM and 35.2 nM, respectively. (Z)-Norendoxifen can be used in breast cancer research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tamoxifen derivative-1 | Tamoxifen derivative-1 is a derivative of Tamoxifen (HY-13757A) with reduced affinity for estrogen receptor (ER). Tamoxifen derivative-1 blocks estrogen-induced activity, inhibits estrogen-stimulated uterine growth, and exhibits uterotrophic activity in immature rats. Tamoxifen derivative-1 can be used in research related to breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Endoxifen (Z-isomer) | 99.19% | Endoxifen Z-isomer is an orally active selective PKCβ1 inhibitor with an IC50 of 360 nM against human PKCβ1. Endoxifen Z-isomer also acts as an estrogen receptor modulator and antiestrogen. Endoxifen Z-isomer binds to and blocks ERα, ERβ and PKCβ1, inhibits estrogen and PI3K/AKT/mTORC1 signaling pathways, suppresses the expression of genes associated with cell cycle, cell proliferation and extracellular matrix remodeling, and induces apoptosis, reactive oxygen species (ROS) production and hypoxic features. Endoxifen Z-isomer inhibits tumor growth in breast tumor and glioblastoma models, reduces bone turnover and blood lipid levels, and does not require metabolism via CYP2D6. Endoxifen Z-isomer can be used in research related to ER+ breast cancer, invasive breast cancer, glioblastoma multiforme, type I bipolar disorder, desmoid tumor, gynecological malignancies, melanoma and hormone receptor-positive solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Endoxifen hydrochloride | 98.04% | Endoxifen hydrochloride is a key active metabolite of Tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen hydrochloride has the potential for breast cancer study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Endoxifen (E-isomer) | 98.02% | Endoxifen E-isomer (E-Endoxifen), an E-isomer of Endoxifen, is an impurity in Endoxifen Z-isomer agent substance. Endoxifen E-isomer exhibits antiestrogenic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Endoxifen | 99.51% | Endoxifen is a key active metabolite of tamoxifen (TAM) with higher affinity and specificity to estrogen receptor that also inhibits aromatase activity. Endoxifen has the potential for breast cancer study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
